David Lillicrap Selected Research

Hemophilia A (Haemophilia)

9/2022	Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action.
4/2022	Long-Term Follow-up of Liver-Directed, Adeno-Associated Vector-Mediated Gene Therapy in the Canine Model of Hemophilia A.
1/2022	Immune complications and their management in inherited and acquired bleeding disorders.
1/2022	Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.
10/2021	A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.
7/2021	Gene therapy for hemophilia: Current status and laboratory consequences.
3/2021	Hemophilia Gene Therapy: Approaching the First Licensed Product.
1/2021	Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
11/2020	The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assays.
5/2020	Hemophilia gene therapy knowledge and perceptions: Results of an international survey.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Lillicrap Research Topics

Disease

61	Hemophilia A (Haemophilia) 09/2022 - 04/2002
22	Hemorrhage 10/2022 - 03/2003
10	Thrombosis (Thrombus) 01/2022 - 06/2010
5	von Willebrand Diseases (von Willebrand's Disease) 10/2022 - 01/2007
5	COVID-19 12/2021 - 03/2021
4	Type 3 von Willebrand Disease 01/2022 - 01/2013
4	Thrombocytopenia (Thrombopenia) 11/2021 - 03/2003
4	Type 1 von Willebrand Disease 08/2020 - 07/2003
4	Hemophilia B (Haemophilia B) 12/2017 - 11/2005
3	Type 2 von Willebrand Disease 06/2010 - 08/2004
2	Obesity 01/2022 - 12/2020
2	Venous Thromboembolism 10/2021 - 12/2020
2	Critical Illness (Critically Ill) 07/2021 - 01/2021
2	Wounds and Injuries (Trauma) 01/2021 - 01/2019
2	Disease Susceptibility (Diathesis) 01/2019 - 03/2003
1	Vomiting 01/2022
1	Seizures (Absence Seizure) 01/2022
1	Headache (Headaches) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Pathologic Constriction (Stenosis) 10/2021
1	Hypersensitivity (Allergy) 03/2021
1	Disseminated Intravascular Coagulation 01/2021
1	Sepsis (Septicemia) 01/2021
1	Venous Thrombosis (Deep-Vein Thrombosis) 12/2020
1	Dysbiosis 01/2020
1	Vascular System Injuries 10/2016
1	Human Influenza (Influenza) 01/2016

Drug/Important Bio-Agent (IBA)

44	Factor VIII (Coagulation Factor VIII)IBA 04/2022 - 09/2002
19	von Willebrand FactorIBA 01/2022 - 07/2003
14	AntibodiesIBA 01/2022 - 12/2004
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2003
8	Hemostatics (Antihemorrhagics)IBA 07/2021 - 01/2006
6	Factor IX (Coagulation Factor IX)FDA LinkGeneric 07/2021 - 03/2002
5	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 10/2022 - 01/2013
5	Blood Coagulation Factors (Coagulation Factor)IBA 01/2022 - 09/2010
5	Immunoglobulin G (IgG)IBA 01/2020 - 05/2015
5	Pharmaceutical PreparationsIBA 01/2020 - 01/2008
4	Heparin (Liquaemin)FDA LinkGeneric 12/2021 - 03/2021
4	fibrin fragment D (D-dimer)IBA 11/2021 - 03/2021
4	ferric chlorideIBA 01/2021 - 06/2010
4	AntigensIBA 01/2021 - 11/2005
4	Neutralizing AntibodiesIBA 01/2020 - 12/2010
3	CollagenIBA 09/2014 - 01/2013
3	CytokinesIBA 07/2009 - 03/2003
2	7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)IBA 04/2022 - 03/2016
2	DNA (Deoxyribonucleic Acid)IBA 10/2021 - 12/2013
2	AnticoagulantsIBA 07/2021 - 03/2021
2	Thrombin FDA Link 01/2021 - 11/2005
2	Antigen-Antibody Complex (Immune Complex)IBA 11/2018 - 06/2014
2	Thromboplastin (Tissue Factor)IBA 07/2018 - 04/2012
2	IsoantibodiesIBA 02/2015 - 08/2013
2	NucleotidesIBA 08/2009 - 11/2004
2	Interleukin-6 (Interleukin 6)IBA 07/2009 - 03/2003
1	Cysteine (L-Cysteine)FDA Link 10/2022
1	Valoctocogene RoxaparvovecIBA 09/2022
1	AutoantibodiesIBA 01/2022
1	ChAdOx1 nCoV-19IBA 11/2021
1	VaccinesIBA 11/2021
1	Ad26COVS1IBA 11/2021
1	RivaroxabanIBA 03/2021
1	apixabanIBA 03/2021
1	edoxabanIBA 03/2021
1	Dabigatran FDA Link 03/2021
1	Fibrinogen (Factor I)FDA Link 03/2021
1	Hemoglobins (Hemoglobin)IBA 03/2021
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 03/2021
1	Nucleic AcidsIBA 03/2021
1	Prothrombin (Factor II)IBA 03/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 03/2021
1	Warfarin (Coumadin)FDA LinkGeneric 03/2021
1	Biomarkers (Surrogate Marker)IBA 03/2021
1	ABO Blood-Group SystemIBA 01/2021
1	Dacarbazine (DIC)FDA LinkGeneric 01/2021
1	Fibrillar CollagensIBA 01/2021
1	multimerinIBA 01/2021
1	Histones (Histone)IBA 01/2021
1	3' Untranslated Regions (3' UTR)IBA 11/2020
1	emicizumabIBA 01/2020
1	Hypochlorous Acid (Hypochlorite)IBA 01/2020
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2020
1	Poly TIBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	ADAMTS13 ProteinIBA 04/2019
1	factor VIII-Fc fusion proteinIBA 01/2019
1	CoagulantsIBA 01/2019
1	BAX 855IBA 01/2019
1	Immunoglobulin M (IgM)IBA 11/2018
1	Factor VIIa (Activated Factor VII)IBA 07/2018
1	recombinant FVIIa (rFVIIa)FDA Link 07/2018
1	Recombinant ProteinsIBA 01/2018
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2018
1	Immunoglobulin Fc FragmentsIBA 01/2018
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2017
1	IntegrinsIBA 09/2014

Therapy/Procedure

25	Therapeutics 01/2022 - 07/2006
2	Artificial Respiration (Mechanical Ventilation) 10/2021 - 03/2021
1	Ambulatory Care (Outpatient Care) 10/2021
1	Positive-Pressure Respiration (Positive End-Expiratory Pressure) 03/2021
1	Renal Replacement Therapy (Therapies, Renal Replacement) 03/2021
1	Erythrocyte Transfusion 03/2021